Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 2Recurrence 1Non-Small Cell Lung Cancer ALK-positive 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Brain Neoplasms 1Astrocytoma 1Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer 1Advanced Non-Small Cell Lung Cancer 1ALK Positive Non-small Cell Lung Cancer 1

Interventions

Specimen Handling 12Magnetic Resonance Spectroscopy 12Temozolomide 10Radiotherapy 8Radiation 5Surgical Procedures, Operative 3Biopsy 3vorasidenib 2trametinib 2pembrolizumab 2dabrafenib 2Spinal Puncture 2Radiotherapy, Intensity-Modulated 2Genetic Therapy 2Craniotomy 2Bevacizumab 2vocimagene amiretrorepvec 1veliparib 1trastuzumab deruxtecan 1tocilizumab 1ribociclib 1lorlatinib 1atezolizumab 1abexinostat 1Vorinostat 1Transurethral Resection of Bladder 1Standard of Care 1Restraint, Physical 1Protons 1Proton Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Astrocytoma × lorlatinib × 90 days × Clear all
NCT06333899 2026-03-12

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Nationwide Children's Hospital

Phase EARLY_PHASE1 Recruiting
15 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡